Nirmatrelvir/ritonavir

antiviral protease inhibitor combination (nirmatrelvir plus ritonavir)

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Nirmatrelvir/ritonavir has no classical depletion machinery for a 5-day course. Nirmatrelvir is cleared mainly by the kidney (49.6% of drug-related material in urine, 55.0% of that unchanged) and, when dosed with ritonavir, has minimal metabolic clearance; ritonavir is metabolized by CYP3A (major) and CYP2D6 (minor) and leaves mainly in feces (86.4%) [2][1]. The kit is a strong CYP3A inhibitor and inhibits CYP2D6, P-gp and OATP1B1, and neither label in the text read names any vitamin, mineral or food interaction other than the St. John's wort contraindication [1][3]. The reaction rates that matter are dysgeusia (5% vs under 1% in the label, 5.6% vs 0.3% in the main trial) and diarrhea (3% vs 2%) [1][5].

antiviral protease inhibitor combination (nirmatrelvir plus ritonavir) · ATC J05AE30 (WHO ATC/DDD Index [4]) · also sold as Paxlovid (kit); ritonavir alone is Norvir [1][3] · reviewed 2026-10-08. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Nirmatrelvir/ritonavir in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Vitamin D, ritonavir component: higher 25(OH)D or lower odds of low 25(OH)D in HIV cohorts, opposite to the in vitro suppression of activating enzymes; no data for a 5-day course

Yellow — Low

See study details

Ritonavir lowers vitamin D activation enzymes in human cell studies, but in HIV cohorts that name ritonavir, exposure went with lower odds of low 25-hydroxyvitamin D or with rising levels, so there is no deficit to grade; nothing was measured after a short Paxlovid course.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Direction

Reverse or neutral for circulating 25(OH)D in cohorts (an association with better, not worse, status); suppression of activation (1,25(OH)2D) shown only in vitro. Not a deficiency finding. No supplementation implication.

Component split

Ritonavir: all of the data below. Nirmatrelvir: no vitamin D record was retrieved for it in any search; the nirmatrelvir PubMed listings returned no vitamin D study [6][18]. Neither label mentions vitamin D in the text read [1][3].

Regulatory status

Not mentioned in the Paxlovid label text covered by the summarizing tool or in the first 100,000 characters of the Norvir label [1][3].

Population evidence (ritonavir named)

SUN cohort, Dao 2011 [7]: 672 US adults with HIV, 25(OH)D below 30 ng/mL in 70.3%; ritonavir exposure aOR 0.56 (95% CI 0.35 to 0.89) for insufficiency or deficiency (lower odds); efavirenz aOR 1.98 (1.18 to 3.34). MACS, Zhang 2017 [8][29]: 640 men with HIV on effective ART and 99 uninfected; deficiency (below 20 ng/mL) 41% vs 44%; current ritonavir use OR 0.58 (95% CI 0.35 to 0.99, p = 0.044) for deficiency in the second HIV-infected model (Table 2, full text; "an estimated 42% lower odds among current users"; reference category not labeled, implied non-users); ritonavir was the only antiretroviral drug significantly associated with deficiency, with efavirenz OR 1.13 (0.72 to 1.77, p = 0.601) and tenofovir OR 0.75 (0.41 to 1.4) not significant. 1,25(OH)2D (Table 3): ritonavir mean difference +1.97 (95% CI -1.38 to 5.31, p = 0.249), not significant; 1,25(OH)2D was comparable between infected and uninfected men. Kampala children, Piloya 2021 [9]: 375 measured; lopinavir/ritonavir OR 0.27 (0.13 to 0.57) for 25(OH)D below 30 ng/mL (lower odds). Houston pilot, Crutchley 2021 [10]: 34 treatment-naive adults on lopinavir/ritonavir monotherapy, mean 25(OH)D 19.8 (SD 12.1) to 26.3 ng/mL (SD 14.9) at 48 weeks, p = 0.0003 (uncontrolled before-after). India, Deshwal 2019 [11]: 475 on ART; ritonavir-containing regimens listed at 84.90% with low levels, no odds ratio, comparator undefined (ambiguous).

Class cohorts (CLASS EXTRAPOLATION)

Cohorts of "protease inhibitors" in which ritonavir was NOT named in the abstract: lower odds of low vitamin D with PI-based ART in Heliyon 2023 (n = 602, aOR 0.18, 95% CI 0.11 to 0.30), WIHS (n = 1,778, aOR 0.67), a New York cohort (n = 463) and a Spanish cohort (n = 352, higher with PIs than efavirenz); one opposite record (n = 138, PI regimens associated with deficiency, p = 0.016) [14]. Whether ritonavir was in these cohorts is not stated in the abstracts, so they are Tier C for this drug and capped at yellow. Nirmatrelvir was not in any cohort.

Mechanism

Named, Tier B [12][13]: in human hepatocyte (H3B) and monocyte (THP-1) lines, protease inhibitors including ritonavir reduced 25-hydroxylase and 1-alpha-hydroxylase activity and mildly inhibited 24-hydroxylase; in primary human dermal fibroblasts ritonavir down-regulated CYP2R1, up-regulated CYP24A1 and lowered cellular 1-alpha,25(OH)2D3. Concentrations are not in the abstracts, so relevance to a booster dose is unknown.

Cohort test

Ritonavir was in the SUN and MACS exposure variables, in lopinavir/ritonavir for the Kampala and Houston studies. The exposure was chronic (months to years), not 5 days, and in people with HIV. Nirmatrelvir/ritonavir as a product was in no vitamin D study. Efavirenz is a competing exposure in the SUN cohort (aOR 1.98) and may shape the SUN ritonavir estimate; in MACS efavirenz was null (OR 1.13), so the ritonavir association there does not depend on an adverse efavirenz comparator. The SUN reference group is not stated in the abstract (the SUN PDF was opened but only the abstract was visible [30]).

Red/orange hunt

Effect sizes retrieved: SUN aOR 0.56 (0.35 to 0.89); MACS OR 0.58 (0.35 to 0.99) from the full text [29]; Kampala OR 0.27 (0.13 to 0.57); Houston +6.5 ng/mL. Three independent cohorts with ritonavir named (SUN, MACS, Kampala) agree in direction and magnitude, and MACS measured 1,25(OH)2D directly and found no ritonavir-related decrease (+1.97 pg/mL, CI -1.38 to 5.31). All point toward better, not worse, status, so the red and orange tests (a real deficit) fail on direction, not on missing data, and the grade stays a yellow reverse-direction entry. What would change the grade: a cohort measuring low 1,25(OH)2D or low 25(OH)D attributable to ritonavir after adjustment for race and co-drugs; none was found (no record in the class listing measured 1,25(OH)2D [14]; the MACS 1,25(OH)2D result was null [29]).

Counter-evidence held on record

Counter-evidence on record The in vitro suppression (Tier B) and the cohort associations (Tier A for the exposure variable) disagree in direction. Cohort associations in HIV are confounded by efavirenz (which carries the adverse association), race, CD4 count and sampling years. India is ambiguous. Framing caution Do not present ritonavir or Paxlovid as lowering vitamin D. The human signal is the reverse. Nothing here supports vitamin D supplementation for a Paxlovid course.

Vitamin K and warfarin: INR changes with nirmatrelvir/ritonavir are a drug-drug interaction; no vitamin K measurement

Yellow — Low

See study details

The Paxlovid label tells prescribers to monitor INR with warfarin, and case-level data show both INR rises and falls, but the mechanism is CYP-mediated warfarin exposure change, not vitamin K depletion, and vitamin K status was never measured.

Full detail and limits

Direction

Drug-drug interaction (Hard Rule 4): effect of the drug on a medicine, not on a nutrient. Not a vitamin K deficiency.

Component split

Ritonavir: strong CYP3A inhibitor, also an inducer of CYP2C9, CYP2C19 and CYP1A2 at chronic dosing (Norvir label list; lopinavir/ritonavir phenotyping in 14 volunteers: CYP2C9 +29%, CYP2C19 +100%, CYP1A2 +43%, hepatic CYP3A -77%) [3][20]. Nirmatrelvir: reversible and time-dependent CYP3A inhibitor [2]; not a named warfarin interactant.

Regulatory status

Paxlovid label Section 7.3: "Closely monitor international normalized ratio (INR) if co-administration with warfarin is necessary." Vitamin K is not mentioned in the text read [1].

Population evidence

Case and small-series level for nirmatrelvir/ritonavir [19]: INR 2.7 to 4.0 on day 2 (case report); 1 of 32 patients with INR 5.32 on day 2; a PBPK simulation predicting a fall in simulated INR; an EMR plus FAERS analysis (180 inpatients and 53,709 reports) with lower warfarin bleeding risk for the combination, aOR 0.32 (95% CI 0.14 to 0.69); the Blood 2022 report on Paxlovid and INR was not readable. Ritonavir-containing regimens without nirmatrelvir: S-warfarin AUC ratio 0.72 (90% CI 0.68 to 0.76) with danoprevir/ritonavir [20].

Mechanism

Named for the drug-drug effect only: ritonavir regimens inhibit CYP3A and induce CYP2C9 (see above), and a PBPK simulation had S-warfarin falling slightly while R-warfarin rose substantially [20][19]. No mechanism involving vitamin K was found.

Cohort test

Nirmatrelvir/ritonavir was in the case series; the vitamin K probe studies used other ritonavir regimens and did not measure vitamin K status.

Red/orange hunt

No study measured vitamin K, PIVKA-II or osteocalcin with ritonavir (10-record listing, ritonavir in all) [20], so no direct nutrient effect size exists to retrieve.

Counter-evidence held on record

Counter-evidence on record Directions conflict across sources (INR increases in cases, a simulated INR decrease, lower bleeding in a database analysis), and the Blood 2022 report could not be read. Framing caution Vitamin K intake is not the remedy for a Paxlovid-related INR change; adjustments belong to the prescriber, and consistent vitamin K intake advice for warfarin users is unchanged by this dossier.

Dietary intake: dysgeusia in about 5 to 7% of treated trial participants vs under 1% on placebo; no study measured food intake

Yellow — Low

See study details

Taste disturbance is the most common reaction in the trials and could reduce intake during a 5-day course, but no trial or cohort measured appetite, weight or nutrient intake.

Full detail and limits

Direction

Possible reduced intake through taste change (mechanism class H). A symptom, not a nutrient deficiency.

Component split

The combination was studied as a unit in the trials; the PAX LC trial used placebo plus ritonavir as the comparator, and study-drug-related adverse events were 76% (35/46) vs 55% (27/49), "mostly driven by dysgeusia", which is consistent with a nirmatrelvir contribution, though the abstract does not state the dysgeusia rates by arm [6]. Norvir (ritonavir) label at chronic dosing: taste perversion 16.2% (285 of 1,755) [3]. A FAERS analysis reported a dysgeusia reporting odds ratio of 28.0 vs ritonavir alone and 305.4 vs other COVID-19 therapeutics (a pharmacovigilance disproportionality, not an incidence) [6].

Regulatory status

Paxlovid label, EPIC-HR (1,038 vs 1,053): dysgeusia 5% vs under 1% [1].

Population evidence

EPIC-HR (2,246): dysgeusia 5.6% vs 0.3% [5]. EPIC-PEP (2,736): 5.9% (5-day) and 6.8% (10-day) vs 0.7% placebo. EPIC-SR: treatment-related dysgeusia 5.8%. A 40-person survey of pregnant and lactating users reported dysgeusia in 91.7% of pregnant users (survey, not a trial) [6].

Mechanism

Not stated in the sources read.

Cohort test

Nirmatrelvir/ritonavir was in all trials. None of the retrieved records reports food intake, appetite, weight or nutrition [6].

Red/orange hunt

Effect sizes for the symptom were retrieved from three independent trials (consistent, 5.6 to 6.8% vs 0.3 to 0.7%), but the nutrient-relevant outcome (intake) was not measured anywhere, so the entry cannot be a nutrient finding.

Counter-evidence held on record

Counter-evidence on record The 5-day exposure is short and dysgeusia was reported in a minority of participants; EPIC-HR gave no intake or weight data. Framing caution Taste change is a tolerability issue to be monitored in people with already low intake; it is not evidence of deficiency.

Diarrhea-related fluid and electrolyte loss: small excess in trials (3% vs 2%), large at chronic ritonavir dosing

Yellow — Low

See study details

Diarrhea is a labeled reaction at low frequency in the 5-day course and very common at chronic full-dose ritonavir, which could cause fluid and electrolyte loss, but no electrolyte measurement is linked to it.

Full detail and limits

Direction

Fluid and electrolyte loss through a GI adverse reaction (context flag). Not a nutrient depletion mechanism of the drug.

Component split

Combination in the trials: 3% vs 2% (label) and 3.1% vs 1.6% [1][5]; EPIC-SR treatment-related diarrhea 2.1% [6]. Ritonavir alone at chronic dosing: 67.9% (1,192 of 1,755 adults) with nausea 57.4% [3].

Regulatory status

Listed as a most common adverse reaction in the Paxlovid label and as the most frequent reaction in the Norvir label [1][3].

Population evidence

See the rates above; the post-marketing Paxlovid list in the label includes abdominal pain, nausea and vomiting without rates [1]. No record linked diarrhea on Paxlovid to potassium, magnesium or sodium values.

Mechanism

Absent as a nutrient mechanism.

Cohort test

Nirmatrelvir/ritonavir in the trials; the high chronic rate is ritonavir alone at far higher exposure and cannot be applied to the 5-day course.

Red/orange hunt

No electrolyte or fluid outcome was measured, so no nutrient effect size exists to retrieve.

Counter-evidence held on record

Counter-evidence on record A 1 percentage point excess over placebo in EPIC-HR (3.1% vs 1.6%) is small in absolute terms. Framing caution A tolerability flag only. It does not support electrolyte supplementation.

Potassium and magnesium: hyperkalemia warnings with co-medicines and ritonavir QT/PR effects; no electrolyte measurement with the drug itself

Yellow — Low

See study details

The Paxlovid label names hyperkalemia only through interactions with eplerenone and tolvaptan, and the ritonavir label describes PR interval prolongation and a small QTcF difference at full dose; no potassium or magnesium level change from the drug itself was found.

Full detail and limits

Direction

Excess (hyperkalemia) risk arises from co-administered drugs whose clearance is blocked; QT and PR are cardiac outcomes. Neither is a nutrient depletion. If anything, supplementation would be the hazard for the hyperkalemia signal (Hard Rule 5).

Component split

Paxlovid label: eplerenone "contraindicated due to potential for hyperkalemia"; tolvaptan "potential for dehydration, hypovolemia and hyperkalemia"; QT mentioned only in the anticancer drug row [1]. Ritonavir (Norvir label): "prolongs the PR interval in some patients"; Section 12.2 mean QTcF difference from placebo 5.5 ms at 400 mg twice daily (as summarized) [3]. Nirmatrelvir: no QT or electrolyte data found [22].

Regulatory status

As above. Hypokalemia and hypomagnesemia were not found in the label text read [1][3].

Population evidence

"nirmatrelvir QT": two records, no QT data; "nirmatrelvir hyperkalemia": no results. Ritonavir QT cohorts are COVID-19 inpatients on lopinavir/ritonavir, usually with hydroxychloroquine or azithromycin (for example median QTc 438 to 452 ms vs 433 to 440 ms; 23% extreme QTc prolongation on triple therapy), confounded by the co-medicines, and not Paxlovid [22].

Mechanism

Not stated in the label text read beyond the general strong CYP3A inhibitor statement; the hyperkalemia warnings are written as contraindication or interaction rows. QT: not stated for nirmatrelvir.

Cohort test

Label statements are on the product. QT cohorts have ritonavir in the cohort but with QT-prolonging co-drugs, not nirmatrelvir.

Red/orange hunt

No study measured potassium or magnesium after nirmatrelvir/ritonavir; the QT numbers are confounded; no second Tier A source with the nutrient measured exists.

Counter-evidence held on record

Counter-evidence on record A thorough QT study result for this combination was not found in the sources read. Framing caution Hyperkalemia risk is with specific co-medicines, so potassium supplements or potassium-sparing drugs should be reviewed by a prescriber; no supplementation is recommended.

Glucose and lipids: ritonavir lowers insulin sensitivity and raises triglycerides at higher or chronic exposure; a single 200 mg boosting dose did not change insulin sensitivity

Yellow — Low

See study details

Hormonal and metabolic effects of ritonavir are dose and duration dependent: single 800 mg or 10 days of lopinavir/ritonavir lowered insulin sensitivity in healthy volunteers, a single 200 mg dose did not, and the Norvir label reports hyperglycemia and lipid elevation at chronic dosing.

Full detail and limits

Direction

Drug effect on glucose and lipid regulation (hormone/metabolic outcome). Not a nutrient deficiency (Hard Rule 2); no nutrient is measured.

Component split

Ritonavir only. Nirmatrelvir: no glucose or lipid finding in the labels read [1].

Regulatory status

Norvir label: "New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and hyperglycemia have been reported"; hypertriglyceridemia 9.0% and hypercholesterolemia 3.0% in 1,755 adults; laboratory abnormalities cholesterol above 240 mg/dL 44.8% and triglycerides above 800 mg/dL 33.6% with ritonavir alone; "Triglyceride and cholesterol testing should be performed prior to initiating NORVIR therapy" [3]. Paxlovid label: statin interactions (lovastatin and simvastatin contraindicated, atorvastatin temporary discontinuation) but no glucose or lipid statement in the text read [1].

Population evidence

Healthy-volunteer trials [21]: single 200 mg dose, no change (glucose disposal 8.59 +/- 0.83 vs 8.51 +/- 0.64, P = 0.89); single 800 mg dose, insulin sensitivity -15% (P = 0.008); lopinavir/ritonavir for 10 days, clamp insulin sensitivity -25% (P < 0.001) vs no significant change with atazanavir/ritonavir (P = 0.132). A pediatric HIV cohort on lopinavir/ritonavir (n = 28) had hypertriglyceridemia in 75%.

Mechanism

Named in the sources: PI effects on insulin-mediated glucose disposal; ritonavir raising triglycerides and VLDL cholesterol (review).

Cohort test

Ritonavir was in every cohort. The booster-dose evidence is a single 200 mg dose; no 5-day study was found. Nirmatrelvir was in none.

Red/orange hunt

No nutrient is being measured, so no red or orange applies; effect sizes were retrieved for the metabolic outcome and are bounded by dose and duration.

Counter-evidence held on record

Counter-evidence on record The one booster-dose trial found no change in insulin sensitivity [21]. Framing caution A metabolic side effect profile of ritonavir, relevant mostly to chronic use. It is not a micronutrient finding and does not call for dietary change.

St. John's wort: herb-to-drug interaction, contraindicated in the label (loss of antiviral response); not a depletion

Yellow — Low

See study details

St. John's wort is a strong CYP3A inducer that the label says must not be co-administered because of potential loss of virologic response and possible resistance; the relationship runs from the herb to the drug.

Full detail and limits

Direction

Herb or supplement lowering drug exposure (Hard Rule 4): a timing and avoidance interaction, not a nutrient depletion.

Component split

Paxlovid label: St. John's wort listed as a strong CYP3A inducer; "Co-administration contraindicated due to potential loss of virologic response and possible resistance" [1]. Norvir label: "Contraindicated due to potential for loss of virologic response and possible resistance to NORVIR" [3].

Regulatory status

Contraindicated in both labels (Section 4 and the interaction tables).

Population evidence

No clinical interaction study with nirmatrelvir was found. The PubMed "grapefruit ritonavir" listing contained no St. John's wort and ritonavir record [26].

Mechanism

Named in the label: induction of CYP3A reducing concentrations of the combination [1].

Separation interval

The label does not give a washout interval in the text read; avoid the combination and ask the prescriber or pharmacist about timing.

Counter-evidence held on record

Framing caution Reduced antiviral exposure is the risk. This is advice to avoid the herb during treatment, not a nutrient finding.

Grapefruit: food-to-drug CYP3A direction; neither label names it, and a CYP3A probe trial found ritonavir inhibition far larger than grapefruit juice

Yellow — Low

See study details

Grapefruit juice inhibits CYP3A modestly, ritonavir inhibits it far more strongly, and no source tested grapefruit with nirmatrelvir/ritonavir, so any added effect is unquantified.

Full detail and limits

Direction

Food affecting drug exposure (Hard Rule 4), not a nutrient depletion.

Component split

Label: grapefruit not found in the Paxlovid text read or the Norvir text read [1][3]; the Drugs.com page for Paxlovid also lists none [28] (Tier D). Ritonavir comparison trial: triazolam AUC +50% with grapefruit juice vs about 22 to 42-fold with ritonavir 400 mg daily for 10 days [26]. Nirmatrelvir: no grapefruit data.

Regulatory status

Silent in the label text read; Section 2.1 of the Paxlovid label states it can be taken with or without food [1].

Population evidence

A volunteer study with 6 to 7 per cohort (Clin Pharmacol Ther 2006) and a rat study with lopinavir [26]. Both are Tier B pharmacology comparisons, not nirmatrelvir/ritonavir cohorts.

Mechanism

CYP3A inhibition, measured with a triazolam probe; ritonavir produced a far larger probe AUC increase than grapefruit juice in that study [26].

Counter-evidence held on record

Framing caution No basis was found to state that grapefruit is harmful or harmless with Paxlovid. Follow the prescriber and pharmacist guidance.

Zinc

Not graded — disclosed evidence gap

See study details

No evidence was found that ritonavir or nirmatrelvir alters zinc absorption, status or loss; the one ritonavir-regimen zinc study found runs from zinc to the antiretroviral drug.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C source was found that supports a yellow grade for zinc depletion or absorption, and no circulating consumer claim about zinc and this drug was found to rebut. A zinc-related dysgeusia explanation was not found in any source read, so nothing is carried. This is a disclosed gap, not a finding of safety.

What was searched

Paxlovid label and Norvir label text read (no zinc statement) [1][3]. PubMed "ritonavir zinc" (25 results, 10 read) [23]: a 16-patient study of zinc sulfate 125 mg daily given with atazanavir/ritonavir lowered atazanavir exposure (AUC0-24 geometric mean ratio 0.78) and total bilirubin (about 20% at 14 days); a 113-patient RCT with zinc in both arms; protocols and reviews. The Drugs.com page names no mineral [28]. Repair pass [35]: "HIV antiretroviral zinc plasma concentrations protease inhibitor" (5 records: four are assay-method papers that use zinc sulfate as a reagent, and the fifth, Ann Nutr Metab 2000, 44 patients before and during HAART, names no protease inhibitor and gives no zinc values); "nirmatrelvir zinc" (6 records, none reporting zinc status or a zinc interaction with nirmatrelvir/ritonavir with numbers; one hypothesis review proposes that co-administration be studied); "serum zinc HIV highly active antiretroviral therapy lopinavir" (fetch error, likely zero results).

Direction note (Hard Rule 4)

The atazanavir/ritonavir finding is a nutrient-to-drug effect on atazanavir, a different protease inhibitor; it says nothing about nirmatrelvir exposure or about zinc status, and is not carried into any entry.

Channel outcomes

Worked: labels, PubMed listings including the nirmatrelvir-specific phrasing. Blocked: open-web consumer searches (budget exhausted). Result: no drug-specific zinc status record on the channel that worked; the zinc-to-atazanavir study is a Hard Rule 4 direction and stays out of the grade. Mostly a genuine gap, with the open-web consumer audit still outstanding.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, ritonavir component: lower membrane potential in human cell lines and in PBMCs during a lopinavir/ritonavir regimen; attribution to ritonavir alone not possible

Yellow — Low

See study details

Ritonavir depolarizes mitochondria in several human cell types at tested concentrations, and PBMC membrane potential fell over 4 weeks of a lopinavir/ritonavir-containing regimen then recovered; no study isolates ritonavir at booster exposure or examines nirmatrelvir.

Full detail and limits

Direction

Drug effect on a cell-level function (excess burden). Not a nutrient deficiency (Hard Rule 2). No supplementation implication.

Component split

Ritonavir: Tier B in vitro data and one combination-regimen human study [15]. Nirmatrelvir: no mitochondrial or respirometry record retrieved; the nirmatrelvir PubMed listings returned none [6][18][27].

Regulatory status

The Paxlovid label carries a hepatotoxicity warning for ritonavir (transaminase elevations, clinical hepatitis, jaundice) [1]; the Norvir label lists postmarketing hepatic dysfunction including fatalities and pancreatitis [3]. The labels do not attribute these to mitochondrial injury.

Population evidence

Human PBMCs in vivo [15] (PMID 21314473): 18 HIV-uninfected adults on post-exposure prophylaxis with lopinavir/ritonavir plus emtricitabine/tenofovir for 4 weeks; mitochondrial membrane potential decreased significantly (linear p = 0.0015, quadratic p = 0.0039), normalized several weeks after stopping; apoptosis unchanged (p = 0.42). Combination regimen: the effect cannot be assigned to ritonavir. Human cell lines [15]: ritonavir alone caused ER stress, membrane potential change, cytochrome c release and caspase-9/7 and PARP-1 activation in Huh-7.5, 293T, HeLa and HepaRG cells (PMID 30386960); ritonavir 15 micromol/L reduced membrane potential in THP-1 and PBMC-derived foam cells (PMID 17591975); damage at 25 and/or 50 micromol/L in SH-SY5Y cells (PMID 27607424, listing level). A cardiomyocyte study found ritonavir, not amprenavir, depolarized the membrane potential (PMID 20736017, species not clearly human). No abstract gives numeric membrane potential values.

Mechanism

Named in the abstracts: ER stress leading to mitochondria-mediated apoptosis in hepatic lines; increased mitochondrial ROS and depolarization in cardiomyocytes. Concentrations in most abstracts are not stated, and 15 to 50 micromol/L is a tested range, not a stated plasma exposure.

Cohort test

Ritonavir was in the PBMC cohort only as part of a combination (lopinavir/ritonavir with emtricitabine/tenofovir), so ritonavir was in the cohort but not isolated. Nirmatrelvir was in no cohort. Exposure was 4 weeks, not 5 days.

Red/orange hunt

The only human measurement of a deficit-direction signal (n = 18) is a surrogate (membrane potential) from a mixed regimen, and a second human HAART study (listing level, 10 completers) found membrane potential in naive T cells rising with CD4 recovery (r = 0.66, p = 0.038), the opposite direction. The repair pass searched human mitochondrial DNA outcomes with ritonavir in the regimen [34]: in seven studies of ritonavir-boosted regimens (n = 6 to 78 each; all listing-level, no CIs), mtDNA or respiratory-chain readouts were stable or rose, mostly when NRTIs were removed while the boosted protease inhibitor continued (for example 78 patients on ritonavir-boosted indinavir plus efavirenz, PBMC mtDNA 206 to 278 copies/cell, P <.001; 6 patients switched to saquinavir/ritonavir, oxygen consumption +194%, P <.05). These show no ritonavir-attributable mtDNA depletion, but they are not a test of ritonavir alone (NRTI withdrawal is the confounder). No second independent Tier A source with consistent deficit direction and ritonavir isolated exists, so orange and red are not met.

Counter-evidence held on record

Counter-evidence on record Mouse liver mitochondria from animals given two other antiretroviral products showed no change in respiration states, RCR, ROS or UCP2 (ritonavir not a named agent) [16]. Human mtDNA copy number was stable or rose in cohorts on ritonavir-boosted protease inhibitor regimens, including an NRTI-free lopinavir/ritonavir plus efavirenz pilot (20 patients, median 478.6 copies/cell at months 12 and 24, 324.4 at month 36, p = 0.5 for month 12 vs 36) [34]; in a zidovudine, zalcitabine and ritonavir arm mtDNA was depleted in every treated patient, but the nucleoside analogues are the established cause and the arm cannot isolate ritonavir [34]. Membrane potential is a surrogate, not a measure of ATP output (see the ATP entry). Framing caution A cell-culture and combination-regimen signal. It does not show mitochondrial injury from a 5-day Paxlovid course and gives no basis for mitochondrial or antioxidant supplements.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, ritonavir component: increased superoxide and mitochondrial ROS in cell studies; no human antioxidant-capacity measurement found

Yellow — Low

See study details

Ritonavir increased superoxide in human THP-1 and PBMC-derived cells at 15 micromol/L and mitochondrial ROS in cardiomyocytes; no human glutathione, MDA or antioxidant-enzyme measurement was found for ritonavir or nirmatrelvir.

Full detail and limits

Direction

Drug-induced oxidant burden in vitro (excess). Not a nutrient deficiency; no antioxidant supplementation is implied.

Component split

Ritonavir only. Nirmatrelvir: no oxidative stress record retrieved on the channels tried.

Regulatory status

Neither label makes an oxidative stress statement in the text read [1][3].

Population evidence

Cell-level only [15]: superoxide anion "increased significantly" with ritonavir 15 micromol/L in human THP-1 and PBMC-derived foam cells (PMID 17591975, no numbers in the abstract); ROS increased by ritonavir and suppressed by rotenone in ventricular myocytes and HL-1 cells (PMID 20736017). No human trial or cohort with ritonavir measured MDA, glutathione, superoxide dismutase or total antioxidant capacity.

Mechanism

Named: mitochondrial ROS (rotenone-sensitive) in cardiomyocytes; shared with the mitochondrial entry.

Cohort test

Cell studies, not cohorts. Ritonavir was tested as a single agent. Nirmatrelvir was not tested.

Red/orange hunt

No human source measuring a redox marker exists in the retrieved set, so no Tier A source is available to retrieve effect sizes from.

Counter-evidence held on record

Counter-evidence on record The PubMed phrasing "ritonavir mitochondrial toxicity OR oxidative stress human cells" returned ten irrelevant records (the OR operator was mis-parsed); the narrower "ritonavir mitochondrial membrane potential" phrasing supplied the sources above. Framing caution In vitro oxidant signals at tested concentrations; not evidence of depleted antioxidant status in people taking Paxlovid.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron: iron deficiency resolved in children with HIV after a ritonavir-based combination (indication-linked, reverse direction); no iron-loss or absorption deficit attributable to ritonavir or nirmatrelvir

Yellow — Low

See study details

The only human iron measurement with ritonavir in the regimen shows iron status improving as HIV enteropathy was treated, and a small hemodialysis series on a paritaprevir/ritonavir regimen showed no hemoglobin or ferritin change; nothing was measured after a nirmatrelvir/ritonavir course.

Full detail, limits and 2 references

Direction

Reverse or neutral. Iron deficiency in the children was a feature of the untreated disease (confounding by indication, Hard Rule 6) and fell with treatment; it is not a ritonavir depletion. Not an iron-deficiency finding for this drug and not a reason to supplement.

Component split

Ritonavir: the data below, all from combination regimens (a ritonavir-based combination in children; ritonavir 75 mg inside a four-drug HCV regimen). Nirmatrelvir: no iron, hepcidin or ferritin record was retrieved. The earlier ferritin listing contained only COVID-19 inflammation records [24].

Regulatory status

No iron statement in the Paxlovid or Norvir label text read [1][3].

Population evidence

Children with advanced HIV, JAIDS 1999 [31] (PMID 10428109): 10 children, intestinal absorption tests (D-xylose, steatocrit, fecal alpha-1-antitrypsin, serum iron) before and after 3 and 6 months of ritonavir-based combination therapy. At enrollment most children had malabsorption, steatorrhea, protein loss or iron deficiency (7 of 10 with iron deficiency per the PubMed listing summary; the OpenAlex summary says "most"); iron-related abnormalities resolved by 6 months with lower viral load, higher CD4 and catch-up growth. Uncontrolled before-after design; raw iron values, CIs and p-values were not obtained. Hemodialysis HCV series, Hemodial Int 2019 [32] (PMID 30762283): 10 patients on ombitasvir, paritaprevir, ritonavir 75 mg and dasabuvir for 12 weeks (3 also on ribavirin); hemoglobin, white cell count, platelets and ferritin "similar to pretreatment values", and weekly erythropoietin and monthly intravenous iron doses were unchanged; no numerical values in the abstract. Iron and erythropoietin were clinician-managed, so the null is weak evidence. Search yield [31][33]: PubMed "ritonavir iron" (12 results, 10 shown) was read after four earlier 429s; the other eight shown records were CYP3A4 heme-iron enzymology papers, an omeprazole review, and a COVID-19 tocilizumab/iron-chelator series where lopinavir/ritonavir was background therapy. "ritonavir hemoglobin anemia HIV" (6 results) gave no regimen-stratified hemoglobin or iron outcome.

Mechanism

Absent. Ritonavir binds the heme iron of CYP3A4 (enzyme inhibition), which is not an effect on body iron. No hepcidin, absorption or loss mechanism for ritonavir or nirmatrelvir was found.

Cohort test

Ritonavir was in both regimens but never isolated, in children with HIV and in hemodialysis patients with HCV; neither population resembles a 5-day Paxlovid course. Nirmatrelvir was in no cohort.

Red/orange hunt

No deficit-direction iron signal exists for ritonavir to grade, so red and orange fail on direction. Effect sizes could not be retrieved for the children's study (single-record PubMed lookup returned 429 once; the OpenAlex record gave a paraphrased abstract only), and the hemodialysis abstract has no numbers. A second independent cohort measuring ferritin or hepcidin with ritonavir isolated was not found.

Counter-evidence held on record

Counter-evidence on record Ferritin in the COVID-19 records is an inflammation marker, not iron status [24]. The children's improvement is attributed by the authors to treatment of the infection, not to a nutrient effect of ritonavir. Ribavirin, not ritonavir, is the anemia cause named in hepatitis C records [25]. Framing caution Do not present ritonavir or Paxlovid as lowering iron, and do not read this entry as showing that Paxlovid improves iron status. It is an indication-linked context flag; iron supplementation is not supported by these sources.

Copper

Not graded — disclosed evidence gap

See study details

No evidence was found that ritonavir or nirmatrelvir alters copper absorption, status or loss, and no circulating claim about copper and Paxlovid was found.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

Why no grade: Dual condition met: no Tier B or C source was found that supports even a yellow grade, and no circulating consumer claim about copper and this drug was found to rebut. This is a disclosed gap, not a finding of safety; re-check when web search and Europe PMC are available.

What was searched

Paxlovid label text read (no copper statement) [1]; Norvir label first 100,000 characters (none) [3]. PubMed "ritonavir copper" (no format parameter): the tool reported 0 results, "No results were found" [24]. The "ritonavir zinc" listing returned no copper study [23]. The Drugs.com Paxlovid food page names no mineral [28]. The first query combining three terms ("ritonavir zinc copper iron") returned a 404, read as a zero-result page. Repair pass [35]: "ritonavir ceruloplasmin" (fetch error, most likely a zero-result page, not confirmed); "HIV antiretroviral serum copper" (8 records: none names ritonavir, lopinavir/ritonavir or a protease inhibitor, and copper values are absent from the abstracts, for example Am J Clin Nutr 2000 and Br J Nutr 2007 report copper without regimen stratification); a Europe PMC REST search "ritonavir AND (copper OR ceruloplasmin)" returned HTTP 429 and was not read.

Channel outcomes

Worked: DailyMed labels (via summarizer), PubMed listings. Blocked: open-web search (the shared search budget was exhausted when retried in the repair pass) and Europe PMC (429). A nirmatrelvir-specific copper PubMed query was not run. Result: zero ritonavir-specific copper records on the channel that worked, one query un-run and one blocked. This is mostly a genuine literature gap for ritonavir, with a residual tooling limit.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk: composition differences in people on ritonavir-boosted regimens (confounded by HIV and co-drugs); no Paxlovid microbiome study found

Yellow — Low

See study details

Cohorts of people with HIV on ritonavir-boosted protease inhibitor regimens show altered gut communities relative to uninfected controls, but ritonavir is not separable from HIV, the boosted drug or duration, and no study followed Paxlovid users.

Full detail, limits and 1 references

Direction

Disturbance of the gut microbial community (a risk entry). Not a nutrient deficiency; no supplementation implication.

Component split

Ritonavir: present as the booster inside PI/r regimens (atazanavir, darunavir, lopinavir), never isolated. Nirmatrelvir: no study. Nirmatrelvir/ritonavir as a product: no study was found with four phrasings [18].

Regulatory status

Paxlovid label, EPIC-HR: diarrhea 3% vs 2% (placebo) [1]. Norvir label, chronic dosing in HIV: diarrhea 67.9% (1,192 of 1,755 adults) and nausea 57.4% [3]. Neither label states a mechanism or names the gut flora.

Population evidence

CLASS EXTRAPOLATION from combination regimens [17]: a randomized trial (88 ART-naive adults, NCT02337322) found a dolutegravir regimen raised richness and diversity while ritonavir-boosted darunavir did not (no numbers in the abstract); 16 viremic patients showed lower alpha diversity with NNRTI regimens than with PI/r after 1 year; Cameroonian children on PI/r diverged more from uninfected controls (87 vs 82 children); a Mexican cohort found Faecalibacterium prausnitzii depleted on both PI/r and efavirenz regimens (p < 0.05). Treated-HIV microbiome shifts are present with regimens that do not contain ritonavir, so ritonavir is not the identified cause.

Mechanism

Absent as a named mechanism for ritonavir. One in vitro study tested lopinavir/ritonavir on gut microflora glycosidases but did not report ritonavir separately [17].

Cohort test

Ritonavir was in the exposure only as a booster within named PI regimens, for months to years, in people with HIV. Nirmatrelvir/ritonavir for 5 days was in no cohort. Capped at yellow.

Red/orange hunt

Looked for a Paxlovid (including rebound or post-COVID) microbiome study: none on four PubMed phrasings; effect sizes are absent from the abstracts of the HIV records and a second, independent, ritonavir-isolating cohort does not exist in the retrieved set.

Counter-evidence held on record

Counter-evidence on record Gut barrier markers in an RCT of boosted PIs vs raltegravir showed no PI/r-specific rise (zonulin rose more with raltegravir, P =.02), and that trial did not measure microbiota [17]. HIV infection itself alters the microbiome. Framing caution Do not describe Paxlovid as disrupting the gut microbiome; the evidence is from chronic boosted regimens in HIV, not from a 5-day antiviral course.

PubMed listing "ritonavir gut microbiota" (format=pubmed; 11 results, 10 shown), summarized by a fetch tool. — Abstract level, no full texts. 41781390 (Nat Commun 2026): RCT NCT02337322, 88 ART-naive adults, ritonavir-boosted darunavir vs a dolutegravir regimen, dolutegravir raised richness and diversity and darunavir/ritonavir did not (no numbers). 33346662 (ACS Infect Dis 2021): 16 viremic patients, 16S before and after 1 year of ART; alpha diversity fell significantly with NNRTI regimens vs PI/r; Prevotella fell after ART (P = 0.00001). 33828220 (Sci Rep 2021): Cameroon, 87 children with HIV vs 82 uninfected; PI/r children diverged more from controls than NNRTI children. 28262770 (Sci Rep 2017): Mexico, PI/r vs efavirenz vs uninfected; diversity lower in treated HIV (p < 0.05); Faecalibacterium prausnitzii depleted in both treatment groups. 30137242 (Clin Infect Dis 2019): RCT of atazanavir/r, darunavir/r or raltegravir, gut barrier markers only (zonulin rose more with raltegravir than PI/r at week 96, P =.02), not microbiota. 33964992 (Pharmazie 2021): in vitro gut-microflora glycosidase study of eight anti-coronavirus drugs at 100 micromol/L including lopinavir/ritonavir; ritonavir not reported separately.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production, ritonavir component: no direct ATP measurement for free ritonavir; membrane potential loss is the only surrogate

Yellow — Low

See study details

No study measured ATP content or respiration with free ritonavir or nirmatrelvir; the mechanistic case rests on reduced mitochondrial membrane potential in human cells and a qualitative ATP decrease with a polymer-bound ritonavir conjugate in HeLa cells.

Full detail and limits

Direction

Possible reduction in cellular energy output (drug effect, not a nutrient finding).

Component split

Ritonavir only; nirmatrelvir not studied.

Regulatory status

No label statement on ATP or energy production in the text read [1][3].

Population evidence

None in humans for ATP. Cell level [16]: HPMA-bound ritonavir reduced ATP production "significantly" in HeLa cells (PMID 30075311; no values; not free drug). Respiration states, RCR, ROS and UCP2 were unaffected in mouse liver mitochondria from animals given two antiretroviral products (PMID 30187948; ritonavir not a named agent). Membrane potential loss is documented separately [15].

Mechanism

Plausible through mitochondrial depolarization (shared with the mitochondrial entry); ATP itself was not measured.

Cohort test

Not applicable (no cohort). Free ritonavir ATP data: none.

Red/orange hunt

Searches for ATP, oxygen consumption and respiration returned three records and none with numbers, so no effect size could be retrieved for a Tier A source because none exists in the retrieved set.

Counter-evidence held on record

Counter-evidence on record The one animal-tissue record with respirometry found no effect (ritonavir not isolated). Framing caution Do not state that Paxlovid lowers cellular ATP or causes fatigue through energy depletion; ATP was not measured.

Oxygen delivery/utilization: label-listed anemia in children on ritonavir regimens (outcome only, confounded by co-drugs)

Yellow — Low

See study details

The only signal is a label laboratory finding of grade 3 to 4 anemia in pediatric patients on ritonavir-containing therapy; no hemoglobin, hemolysis or methemoglobin study attributes any change to ritonavir or nirmatrelvir.

Full detail and limits

Direction

Hematologic outcome (not a nutrient deficiency; anemia is not iron deficiency, Hard Rule 2).

Component split

Ritonavir: Norvir label pediatric laboratory data (as summarized, grade 3 to 4 anemia 4%; the label context, comparator and co-administered nucleoside drugs were not verified from the text read) [3]. Nirmatrelvir: the Paxlovid label text covered by the tool lists no anemia [1].

Regulatory status

Paxlovid label: no hemoglobin or anemia statement in the text read [1]. Norvir label: pediatric anemia as above [3].

Population evidence

PubMed "ritonavir hemolytic anemia": three records, all ribavirin-containing hepatitis C regimens with the anemia attributed to ribavirin, or HIV case reports without hemoglobin data [25]. No oxygen saturation, hemoglobin or methemoglobin data for nirmatrelvir/ritonavir were retrieved. Repair-pass searches (ritonavir hemoglobin anemia HIV, 6 records [33]; hemodialysis series [32]) found no ritonavir-attributed hemoglobin change: in 10 hemodialysis patients on ombitasvir, paritaprevir, ritonavir (75 mg) and dasabuvir, hemoglobin and ferritin stayed similar to pretreatment and erythropoietin and iron doses were unchanged (no numbers in the abstract) [32].

Mechanism

Absent for ritonavir or nirmatrelvir on the channels tried.

Cohort test

The label statement comes from combination antiretroviral therapy; ritonavir is in the population but not isolated.

Red/orange hunt

No effect size, comparator or sample size could be retrieved because the label table was summarized without them and no study measured hemoglobin as an outcome of ritonavir.

Counter-evidence held on record

Counter-evidence on record Ribavirin, not ritonavir, is the cause named in the retrieved anemia records [25]. Framing caution A hematologic outcome flag only. It does not imply an iron or oxygen-carrying deficit.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

No white entry: no circulating nutrient-depletion claim for Paxlovid was traced (tooling-limited)
Where it comes from: The consumer-claim audit relied on open-web search, whose shared budget was exhausted. The one consumer page opened (Drugs.com food interactions for Paxlovid, Tier D) names no vitamin, mineral, grapefruit or St. John's wort claim [28].
Why it fails: Nothing to rebut was found, so nothing is published as white. The framing "protease inhibitor courses deplete nutrients" is not supported by any source read, and the closest real signals (dysgeusia, diarrhea, the ritonavir effect on vitamin D enzymes in vitro) are carried as yellow entries with their direction stated. Re-check with web search available before treating the absence of a claim as established.

How the body handles this medication

Metabolism and enzymes: Nirmatrelvir is a CYP3A substrate, but with ritonavir "metabolic clearance is minimal". Ritonavir: major CYP3A, minor CYP2D6. Nirmatrelvir is a reversible and time-dependent CYP3A inhibitor. The kit is a strong CYP3A inhibitor and an inhibitor of CYP2D6, P-gp and OATP1B1. Ritonavir alone "also appears to induce CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2B6" and glucuronosyl transferase (Norvir label, chronic dosing).[2][1][3]
Elimination: Nirmatrelvir: renal elimination; 49.6% of drug-related material in urine, 35.3% in feces, 55.0% of urinary material unchanged; half-life 6.05 h. Ritonavir: hepatic metabolism; 11.3% in urine, 86.4% in feces; 3.5% unchanged in urine; half-life 6.15 h.[2]
Absorption and food: May be taken with or without food. A high-fat, high-calorie meal raised nirmatrelvir fed/fasted ratios to 119.67 (AUCinf) and 161.01 (Cmax), as stated in the label summary read. No absorption transporter or mineral chelation interaction is named in the text read.[1]
Distribution: Plasma protein binding about 69% (nirmatrelvir) and 98 to 99% (ritonavir). Median Tmax 3.00 h (nirmatrelvir) and 3.98 h (ritonavir); steady state by day 2 with about 2-fold accumulation.[1][2]
Renal and hepatic handling: Label: no dosage adjustment in mild renal impairment and none in mild (Child-Pugh A) hepatic impairment; the summarizing tool did not return the moderate and severe statements, so they are not reproduced here. Hepatotoxicity: "Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir." In the phase 3 trial, aminotransferase increases were no more than 2.4% per a narrative review.[1][27]
Interactions of nutritional interest: St. John's wort contraindicated (loss of virologic response, possible resistance). Warfarin: "Closely monitor international normalized ratio (INR)". Eplerenone and tolvaptan: hyperkalemia warnings. Lovastatin and simvastatin contraindicated; atorvastatin temporary discontinuation to be considered. Grapefruit, vitamin K and all minerals: not mentioned in the label text read.[1][3]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Medication review / before and during the course
Interacting medicines and herbs
Check every medicine and supplement for strong CYP3A inducers (including St. John's wort, contraindicated) and for CYP3A-dependent drugs. Statins, eplerenone, tolvaptan and anticancer drugs are named in the label [1]. This is a medication-reconciliation task for the prescriber or pharmacist, not a nutrient task.
Lab / people on warfarin
INR
The label instructs close INR monitoring when warfarin is used with the kit; case-level data show both rises and falls [1][19]. Vitamin K is not the remedy; adjustments belong to the prescriber.
Lab / liver disease or symptoms
Liver tests
The label warns of transaminase elevations, hepatitis and jaundice with ritonavir; aminotransferase increases were no more than 2.4% in the phase 3 trial per a review [1][27]. Dark urine or jaundice warrants prompt assessment. This is a drug toxicity outcome, not a nutrient finding.
Symptoms / low-intake or frail people
Taste change and diarrhea
Dysgeusia occurs in about 5 to 7% of treated trial participants and diarrhea in about 2 to 3% [1][6]. Watch oral intake and hydration in people with limited reserves. No supplement is indicated.
Cardiac / electrolytes
Potassium, magnesium and ECG
Not routinely indicated. Consider only with heart disease, other QT-prolonging medicines, vomiting or diarrhea, or the interacting drugs named above. Do not supplement potassium unprompted; hyperkalemia warnings exist with specific co-medicines [1][3].
Long-term ritonavir users (not a Paxlovid course)
Glucose and lipids
The Norvir label advises triglyceride and cholesterol testing before starting chronic ritonavir and reports new-onset diabetes and hyperglycemia [3]. These apply to chronic ritonavir therapy, not to a 5-day course.
Not needed
Vitamin D, copper, iron, zinc
No routine testing is supported by the sources read for a Paxlovid course. In people with HIV on chronic ritonavir, vitamin D testing follows standard HIV care; the cohorts retrieved show ritonavir associated with better, not worse, 25(OH)D [7][8][9].

Overlap map, to prevent double counting

Entries that rest on the same underlying source or mechanism. Do not count them as independent confirmation.

Mitochondrial burden
Shares evidence with: Oxidative stress; ATP production
Note: The same ritonavir cell studies (membrane potential, superoxide: PMIDs 17591975, 20736017, 30386960) support all three. ATP rests only on the membrane potential surrogate and one conjugate result. One mechanism, not three lines of evidence.
Mitochondrial burden
Shares evidence with: Hepatotoxicity statement in the labels (monitoring panel)
Note: Hepatic cell-line data (Huh-7.5, HepaRG) and the label warning are different kinds of evidence for the same organ; the labels do not link them.
Vitamin D
Shares evidence with: Glucose and lipids; Oxygen delivery; Iron
Note: No shared source. Vitamin D uses HIV cohorts and two in vitro studies; the metabolic entry uses healthy-volunteer clamps; oxygen delivery uses a label table; iron uses a pediatric absorption study and a hemodialysis series.
Dietary intake (dysgeusia)
Shares evidence with: Diarrhea-related loss
Note: Both rest on the same trial adverse-event tables (EPIC-HR, EPIC-SR, EPIC-PEP) and the Norvir label table.
Gut microbiome risk
Shares evidence with: Diarrhea-related loss
Note: The Norvir and Paxlovid label diarrhea rates are cited in both; the microbiome entry adds HIV cohort data that do not measure diarrhea.
Vitamin K and warfarin
Shares evidence with: St. John's wort; Grapefruit
Note: All three are CYP-mediated drug-interaction statements (CYP3A inhibition or induction) from the labels and the same ritonavir phenotyping literature. They are interactions, not nutrient findings.
Potassium and magnesium (QT)
Shares evidence with: Vitamin K and warfarin
Note: The potassium warning (eplerenone, tolvaptan) and the INR monitoring warning come from the same label drug-interaction table.
Glucose and lipids
Shares evidence with: Mitochondrial burden
Note: One cell study (PMID 17591975, foam-cell cholesterol efflux and membrane potential) appears in both.
Iron
Shares evidence with: Oxygen delivery/utilization
Note: The hemodialysis HCV series (PMID 30762283, hemoglobin and ferritin unchanged) is cited in both, and the hemoglobin and anemia PubMed listing supports both. Counted once. The children's intestinal-function study supports only Iron.
Copper, Zinc
Shares evidence with: None
Note: Independent ungraded entries; the zinc entry cites an atazanavir/ritonavir study that does not inform copper. Neither shares evidence with Iron.

All references used above

Nirmatrelvir/ritonavir

Findings for this medication

What the research found

Vitamin D, ritonavir component: higher 25(OH)D or lower odds of low 25(OH)D in HIV cohorts, opposite to the in vitro suppression of activating enzymes; no data for a 5-day course

Vitamin K and warfarin: INR changes with nirmatrelvir/ritonavir are a drug-drug interaction; no vitamin K measurement

Dietary intake: dysgeusia in about 5 to 7% of treated trial participants vs under 1% on placebo; no study measured food intake

Diarrhea-related fluid and electrolyte loss: small excess in trials (3% vs 2%), large at chronic ritonavir dosing

Potassium and magnesium: hyperkalemia warnings with co-medicines and ritonavir QT/PR effects; no electrolyte measurement with the drug itself

Glucose and lipids: ritonavir lowers insulin sensitivity and raises triglycerides at higher or chronic exposure; a single 200 mg boosting dose did not change insulin sensitivity

St. John's wort: herb-to-drug interaction, contraindicated in the label (loss of antiviral response); not a depletion

Grapefruit: food-to-drug CYP3A direction; neither label names it, and a CYP3A probe trial found ritonavir inhibition far larger than grapefruit juice

Zinc

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden, ritonavir component: lower membrane potential in human cell lines and in PBMCs during a lopinavir/ritonavir regimen; attribution to ritonavir alone not possible

💥Oxidative Stress

Oxidative stress, ritonavir component: increased superoxide and mitochondrial ROS in cell studies; no human antioxidant-capacity measurement found

⚖️Copper and Iron Balance

Iron: iron deficiency resolved in children with HIV after a ritonavir-based combination (indication-linked, reverse direction); no iron-loss or absorption deficit attributable to ritonavir or nirmatrelvir

Copper

🌿Gut Microbiome Risk

Gut microbiome risk: composition differences in people on ritonavir-boosted regimens (confounded by HIV and co-drugs); no Paxlovid microbiome study found

💨Oxygen and ATP Output

ATP production, ritonavir component: no direct ATP measurement for free ritonavir; membrane potential loss is the only surrogate

Oxygen delivery/utilization: label-listed anemia in children on ritonavir regimens (outcome only, confounded by co-drugs)

Claims checked and not supported

No white entry: no circulating nutrient-depletion claim for Paxlovid was traced (tooling-limited)

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output